Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatoma/merbarone. A Southwest Oncology Group study.

Literature DB >> 7775137

Hepatoma/merbarone. A Southwest Oncology Group study.

E A Poplin¹, C M Tangen, W H Harvey, J S Macdonald.

Abstract

Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1994 PMID： 7775137 DOI： 10.1007/bf00873051

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

11 in total

1. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors: G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal: Cancer Date: 1978-11 Impact factor: 6.860

2. Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.

Authors: H L Davis; G Ramirez; F J Ansfield
Journal: Cancer Date: 1974-01 Impact factor: 6.860

Review 3. Clinical trials in primary hepatocellular carcinoma: current status and future directions.

Authors: S R Nerenstone; D C Ihde; M A Friedman
Journal: Cancer Treat Rev Date: 1988-03 Impact factor: 12.111

4. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

Authors: F H Drake; G A Hofmann; S M Mong; J O Bartus; R P Hertzberg; R K Johnson; M R Mattern; C K Mirabelli
Journal: Cancer Res Date: 1989-05-15 Impact factor: 12.701

5. Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study.

Authors: E H Kraut; T Fleming; J S Macdonald; C H Spiridonidis; J E Bradof; L H Baker
Journal: Am J Clin Oncol Date: 1993-08 Impact factor: 2.339

6. Phase I clinical and pharmacological study of merbarone.

Authors: J J Dimaggio; R P Warrell; J Muindi; Y W Stevens; S J Lee; D A Lowenthal; I Haines; T D Walsh; L Baltzer; S Yaldaei
Journal: Cancer Res Date: 1990-02-15 Impact factor: 12.701

7. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

Authors: A Y Chang; K Kim; J Glick; T Anderson; D Karp; D Johnson
Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506

Review 8. Merbarone: an antitumor agent entering clinical trials.

Authors: A Glover; H G Chun; L M Kleinman; D A Cooney; J Plowman; C K Grieshaber; L Malspeis; B Leyland-Jones
Journal: Invest New Drugs Date: 1987 Impact factor: 3.850

9. A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.

Authors: K Y Look; J A Blessing; L Williams; M Morris
Journal: Am J Clin Oncol Date: 1995-10 Impact factor: 2.339

10. Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.

Authors: E H Kraut; J Bendetti; S P Balcerzak; J H Doroshow
Journal: Invest New Drugs Date: 1992-11 Impact factor: 3.850

1 in total

1. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).

Authors: F L Meyskens; J Jacobson; B Nguyen; G R Weiss; D R Gandara; J S MacDonald
Journal: Invest New Drugs Date: 1998 Impact factor: 3.850

1 in total